ArticleBMC infectious diseases2026
Toll-like receptor 5 on monocyte as a biomarker of mortality risk in patients with sepsis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
objectiveTo evaluate the expression of Toll-like receptor 5 on monocyte at ICU admission as a potentially novel early screening biomarker to predict the mortality risk of sepsis.
methodsPatients with sepsis (n = 107), ICU non-septic controls (n = 53) and healthy controls (n = 55) from May 2023 to December 2024 were enrolled. The expression of Toll-like receptor 5 on monocyte were detected by Flow cytometry within 4 h at ICU admission. The efficacy of Toll-like receptor 5 for predicting mortality risk of sepsis were analyzed by receiver operating characteristic curves. The Toll-like receptor 5 was categorized into higher and lower groups on the basis of the cutoff value, and Kaplan-Meier survival rates were analyzed to evaluate the relationship between Toll-like receptor 5 and the mortality risk of sepsis.
resultsToll-like receptor 5 levels on monocyte at ICU admission in patients with sepsis were significantly higher than those in ICU non-septic patients and the healthy controls. The expression of Toll-like receptor 5 on monocyte in septic non-survivors were significantly higher than that in survivors. Moreover, the AUC of Toll-like receptor 5 (0.6983, P = 0.0006) for predicting mortality risk of sepsis were higher than PCT (0.5741, P = 0.2012) ,CRP (0.5820, P = 0.1582) and WBC (0.6381, P = 0.0172), but lower than APACHE II (0.7101, P = 0.0003) and SOFA score (0.7888, P < 0.0001). The AUC of Toll-like receptor 5 combined with SOFA score for estimating 28-day mortality in septic patients increased from 0.6983 to 0.8030 (P < 0.0001). Toll-like receptor 5, SOFA and APACHE II scores at ICU admission were found to be independent predictors of sepsis 28-day mortality. In addition, septic patients with higher Toll-like receptor 5 level (≥ 2.05) had poorer survival than those with lower levels (< 2.05) (P = 0.0002).
conclusionThe expression of TLR5 on monocyte at ICU admission were valuable for predicting the mortality risk of sepsis. These findings can be used as a early screening biomarker to predict the mortality risk of sepsis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.